Innealta Capital’s Precigen PGEN Stock Holding History

Innealta Capital’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-99	Closed	-$156	–	1251
2024 Q2	$156	Buy	+99	New	+$144	﹤0.01%	1639

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Innealta Capital's PGEN Position: Q3 2024 in Review

Innealta Capital sold out of Precigen (PGEN) in Q3 2024, closing a stake of 99 shares — an estimated $156 sold.

Innealta Capital first reported a position in PGEN in Q2 2024 and held it in 1 quarter. The position peaked at $156 in Q2 2024. 127 funds tracked by Wall St. Rank hold PGEN as of Q3 2024.

Innealta Capital reported no remaining Precigen position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 99 Precigen shares in Q3 2024, an estimated $156.
Innealta Capital first reported a position in Precigen in Q2 2024 and held it in 1 quarter.
Innealta Capital's Precigen position peaked at $156 in Q2 2024.
127 funds tracked by Wall St. Rank held Precigen as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.